ARTICLE | Clinical News
XenoPort up on arbaclofen placarbil plans
September 14, 2010 12:47 AM UTC
XenoPort Inc. (NASDAQ:XNPT) gained $1.35 (22%) to $7.55 on Monday after announcing plans to start Phase III testing in 1H11 for arbaclofen placarbil ( XP19986) to treat spasticity in multiple sclerosi...